% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Pils:1032444,
author = {Pils, Marlene and Dybala, Alexandra and Schaffrath, Anja
and Rehn, Fabian and Kutzsche, Janine and Blömeke, Lara and
Tusche, Markus and Özdüzenciler, Pelin and Bujnicki, Tuyen
and Kraemer-Schulien, Victoria and Gramespacher, Hannes and
Schmieschek, Maximilian H. T. and Barbe, Michael T. and
Onur, Oezguer A. and Fink, Gereon R. and Tamgüney,
Gültekin and Bannach, Oliver and Willbold, Dieter},
title = {{E}levated {A}β aggregates in feces from {A}lzheimer’s
disease patients: a proof-of-concept study},
journal = {Alzheimer's research $\&$ therapy},
volume = {16},
number = {1},
issn = {1758-9193},
address = {London},
publisher = {BioMed Central},
reportid = {FZJ-2024-06250},
pages = {223},
year = {2024},
note = {sFIDA was supported by the programs “Biomarkers Across
Neurodegenerative Diseases I + II” of The Alzheimer’s
Association, Alzheimer’s Research UK, and the Weston Brain
Institute [11084, BAND-19-614337]. We are also grateful for
support from The Michael J. Fox Foundation for Parkinson’s
Research [14977, 009889], the ALS Association, and the
Packard Center [19-SI-476]. We received further funding from
the Deutsche Forschungsgemeinschaft [INST 208/616-1 FUGG,
INST 208/794-1 FUGG], Helmholtz Association [HVF0079],
Förderstiftung Dierichs, and Deutsche Alzheimer
Gesellschaft e.V. Selbsthilfe Demenz (DalzG). G.R.F. and
O.A.O. were supported by the Marga and Walter
Boll-Foundation. H.G. was supported by the Cologne Clinician
Scientist Program (CCSP) / Faculty of Medicine / University
of Cologne and received funding from Deutsche
Forschungsgemeinschaft [DFG, FI 773/15 − 1].Open Access
funding enabled and organized by Projekt DEAL.},
abstract = {BackgroundMisfolding and aggregation of amyloid β (Aβ),
along with neurofibrillary tangles consisting of aggregated
Tau species, are pathological hallmarks of Alzheimer’s
disease (AD) onset and progression. In this study, we
hypothesized the clearance of Aβ aggregates from the brain
and body into the gut.MethodsTo investigate this, we used
surface-based fluorescence intensity distribution analysis
(sFIDA) to determine the Aβ aggregate concentrations in
feces from 26 AD patients and 31 healthy controls
(HC).ResultsAβ aggregates were detectable in human feces
and their concentrations were elevated in AD patients
compared to HC (specificity $90.3\%,$ sensitivity
$53.8\%).ConclusionThus,$ fecal Aβ aggregates constitute a
non-invasive biomarker candidate for diagnosing AD. Whether
digestion-resistant Aβ aggregates in feces are secreted via
the liver and bile or directly from the enteric neuronal
system remains to be elucidated.},
cin = {INM-3 / IBI-7},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)IBI-7-20200312},
pnm = {5251 - Multilevel Brain Organization and Variability
(POF4-525) / 5244 - Information Processing in Neuronal
Networks (POF4-524)},
pid = {G:(DE-HGF)POF4-5251 / G:(DE-HGF)POF4-5244},
typ = {PUB:(DE-HGF)16},
pubmed = {39402637},
UT = {WOS:001331211400001},
doi = {10.1186/s13195-024-01597-3},
url = {https://juser.fz-juelich.de/record/1032444},
}